IP Library Granted Patent US 7,040,485
Granted Patent B2
US 7,040,485 · App. 11/174,115 · Granted May 9, 2006

Method and apparatus for packaging a drug-device combination product

Assignee: Codman & Shurtleff, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,040,485
App. No.
11/174,115
Granted
May 9, 2006
Kind
B2
Abstract

A package for a drug-device combination product includes an outer package including a first gas impermeable sheet and a second gas impermeable sheet hermetically sealed there to on three sides. A gas permeable header is attached to an unsealed side of the first sheet and sealed to the second sheet on two sides. The first and second gas impermeable sheets and the header form an interior and an opening communicating with the interior. A gas permeable inner package is disposed within the outer package. A product is sealed within the inner package. The inner package is placed within the outer package and a top end of the header is sealed to the second sheet. The outer package is then sealed by sealing the first gas impermeable sheet to the second gas impermeable sheet at a seal point below the point where the header attaches to the first sheet.

Claims (29)

1. A package for a drug-device combination product, comprising:

an outer package comprising:

a first gas impermeable sheet;

a second gas impermeable sheet hermetically sealed on three sides with the first gas impermeable sheet;

a gas permeable header disposed at an unsealed side of the first gas impermeable sheet and sealed to the second gas impermeable sheet on two sides; and

wherein the first and the second gas impermeable sheets and the gas permeable header form an interior and an opening communicating with the interior; and

a gas permeable inner package designed to hold said drug-device combination product and be disposed within the outer package.

2. The package of claim 1 , wherein the gas permeable inner package is disposed only between the first and the second gas impermeable sheets.

3. The package of claim 1 , wherein the gas permeable inner package is a blister tray.

4. The package of claim 1 , wherein the gas permeable inner package is a pouch.

5. A package for a product, comprising:

a product incorporated with a drug;

a gas permeable inner package sized to contain the product; and

an outer package comprising:

a first sheet comprising:

a gas impermeable section; and

a gas permeable header disposed to a first side of the gas impermeable section;

a second sheet being gas impermeable and hermetically sealed on three sides to the first sheet; and

the first and the second sheets forming an interior and an opening communicating with the interior, wherein the inner package is disposed within the outer package.

6. The package of claim 5 , wherein the gas permeable inner package is disposed only between the gas impermeable section of the first sheet and the second sheet.

7. The package of claim 5 , wherein the gas permeable inner package is a blister tray.

8. The package of claim 5 , wherein the gas permeable inner package is a pouch.

9. The package of claim 5 , wherein the drug is selected from the group comprising antimicrobial agents, antiangiogenesis, antiproliferatives, and anti-inflammatorys.

10. The package of claim 9 , wherein the antimicrobial agents are selected from the group comprising antibiotics, antiseptics, and disinfectants.

11. The package of claim 10 , wherein the antibiotics are selected from the group comprising tetracyclines, penicillins, macrolides, rifampin, gentamicin, vancomycinclindamycin, azithromycin, enoxacin, and combinations thereof.

12. The package of claim 9 , wherein the antimicrobial agent is at least one of Rifampicin and Clindamycin.

13. The package of claim 9 , wherein the antiangiogenesis are selected from the group comprising angiostatin, thalidomide, CC-5013, bevacizumab, squalamine, endostatin, angiostatin, angiozyme, paclitaxel, doxorubicin, epirubicin, mitoxantrone, and cyclophosphamide.

14. The package of claim 9 , wherein the antiproliferatives is at least one of Sirolimus and Paclitaxel.

15. The package of claim 9 , wherein the anti-inflanimatorys are selected from the group comprising ibuprofen, ketoprofen, motrin, or naproxen.

Continuity (2)
Division 1067633300 · Sep 30, 2003
Related Publication 20050241981A1 · Nov 3, 2005